Detalhe da pesquisa
1.
Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
Nature
; 469(7329): 216-20, 2011 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-21124317
2.
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.
Proc Natl Acad Sci U S A
; 108(8): 3336-41, 2011 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-21289283
3.
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.
Cancer Res
; 66(12): 6050-62, 2006 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16778177
4.
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma.
Nat Genet
; 44(10): 1126-30, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22941191
5.
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.
Cancer Res
; 72(8): 2068-78, 2012 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22350409
6.
Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target.
Cancer Res
; 70(7): 2749-58, 2010 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20233875
7.
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.
Nat Genet
; 41(6): 718-23, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19412175
8.
Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
Genes Chromosomes Cancer
; 46(10): 936-49, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17647283